UpStream Bio Inc. UPB 深 沪
等待开盘 08-02 09:30:00 美东时间
15.22
-0.090
-0.59%
华盛通- 最 高15.46
- 今 开14.78
- 成交量 29.63万股
- 最 低 14.21
- 昨 收 15.31
- 总市值 8.19亿
- 52周最高 29.4599
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 5.14
- 委 比 20.00%
- 总股本 5379.37万
- 历史最高 29.4599
- 量 比 0.65
- 振 幅 8.16%
- 历史最低 5.14
- 每 手 1
- 风险率 6.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on ...
07-28 22:29
Upstream Bio Doses First COPD Patient in Phase 2 Trial for Anti-Inflammatory Drug Verekitug
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the first patient has been dosed in
07-08 19:02
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Upstream Bio, Inc. has initiated a Phase 2 clinical trial, VENTURE (NCT06981078), evaluating verekitug, a TSLP receptor antagonist, in patients with moderate-to-severe COPD. The trial will assess its efficacy and safety when administered every 12 or 24 weeks. Verekitug is the only known biologic targeting the TSLP receptor, with potential benefits for COPD treatment. The primary endpoint is the annualized rate of moderate or severe COPD exacerbat...
07-08 11:00
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Upstream Bio, Inc. announced pharmacology modeling data at the EAACI Congress highlighting verekitug's superior potency compared to tezepelumab by targeting the TSLP receptor. Verekitug, a monoclonal antibody, inhibits TSLP signaling, potentially offering broad therapeutic benefits across inflammatory diseases like severe asthma, COPD, and CRSwNP. Data showed complete inhibition of the TSLP/TSLPR complex and greater FeNO reduction with verekitug,...
06-15 11:45
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Upstream Bio will present data on verekitug, a TSLP receptor antagonist, at the EAACI Congress 2025, showcasing its potential for greater potency compared to ligand-targeting approaches. Verekitug, the only TSLP receptor-targeting monoclonal antibody in clinical development, is being tested in Phase 2 trials for severe asthma and chronic rhinosinusitis, with an upcoming trial for COPD. The presentation will highlight translational pharmacology mo...
06-05 11:00
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Upstream Bio, Inc., a clinical-stage biotechnology company developing treatments for inflammatory diseases, announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The webcast will be available on the company's website, with a replay posted afterward. Upstream Bio is advancing verekitug, a monoclonal antibody targeting the receptor for thymic ...
06-04 11:00
Upstream Bio Q1 EPS $(0.51) Misses $(0.49) Estimate, Sales $566.00K Beat $327.50K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. The company reported quarterly sales of $566.00 thousand which beat the
05-06 21:28
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket
Shares of ReShape Lifesciences Inc. (NASDA: RSLS) rose sharply in today's pre-m...
04-10 17:26
Upstream Bio Q3 Sales $613.00K Miss $686.67K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly sales of $613.00 thousand which missed the analyst consensus estimate of $686.67 thousand by 10.73 percent. This is a 0.99 percent increase over sales of $607.00 thousand the
03-12 19:21
TD Cowen Initiates Coverage On Upstream Bio with Buy Rating
TD Cowen analyst Yaron Werber initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating.
2024-11-05 19:28
